Brimonidine Tartrate
Manus Aktteva Biopharma LLP, a global supplier of Brimonidine Tartrate, 70359-46-5 (79570-19-7) offers for your requirements of RND / Development quantities or commercials, based on status of the product. We can also offer its intermediates with supportive technical package required for evaluation.
CAS number:
70359-46-5 (79570-19-7)
Chemical Name:
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine tartrate, Brimonidine Tartrate
Certificate:
GMP, Factory GMP, GMP - SFDA, cGMP, Product GMP, EUGMP, WHO GMP, ISO Certified, USFDA
Application:
For R&D Purpose
Email To:
Your Email:
Your Name:
Note:
Processing....
Synonym
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine tartrate, Brimonidine Tartrate
Specifications
Available on request
Packing
Export worthy packing
Material Safety Data Sheet
Available on request
| Product Name |
CAS No. |
|
| (+)-5-Iodo-2'-deoxyuridine |
54-42-2 |
View | Inquire |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine |
86163-17-9 |
View | Inquire |
| (2E)-3-[1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propenoic acid |
74131-06-9 |
View | Inquire |
| 5-Bromo 6-Amino Quinoxaline |
50538-63-9 |
View | Inquire |
| 5-Bromoquinazolin-6-ylthiourea |
842138-74-3 |
View | Inquire |
Description:
Brimonidine acts on receptors (alpha-receptors) in the blood vessels of the eye causing them to constrict. These blood vessels control the production of the watery fluid that fills the rear of the eye. When the blood vessels constrict there is a decrease in the production of this watery fluid. Brimonidine is used in the treatment of glaucoma. This is a condition where the fluid drainage from the eye is impaired, resulting in fluid build-up and increased pressure in the eye. Brimonidine is used as an eye drop so that it can act directly where it is needed. Brimonidine may also be used to treat glaucoma that does not respond to beta-blocker eye drops.
- Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
- Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)
- Products falling in to controlled substance category / list of schedule drugs shall be exported directly from the manufacturer principals only against receipt of original import permission issued by concerned authorities of the importing country.
- Manus Aktteva Biopharma LLP assumes no responsibility/liability in case of being imparted with goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual. Manus Aktteva makes no representations or warranties of any kind, express or implied, about the originality or reliability with respect to the intellectual property which includes patents in its products or services for any purpose.
- Manus Aktteva Biopharma LLP warns the sellers not to sell any goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual.
- Manus Aktteva Biopharma LLP warns the buyers not to use/procure any goods to achieve a product which might be knowingly causing an infringement of intellectual property in any manner whatsoever which includes patent rights of any individual.
Are you looking for Brimonidine Tartrate with documentation like PMDA - JAPAN, DMF - CANADA, MHRA - UK, DMF - KOREA, AIFA - ITALY, MEDSAFE - NEW ZEALAND, HEALTH CANADA, JDMF, JAPAN - AFM, DMF - CTD, DCGI, ICH, COPP, TDMF, Written Confirmation? Please
click here to send us sourcing request.
Brimonidine Tartrate, 70359-46-5 (79570-19-7), USDMF, EDMF, CEP / COS, TGA - AUSTRALIA, DMF (OPEN PART), DMF (CLOSED PART), TDP, GMP, Factory GMP, GMP - SFDA, cGMP, Product GMP, EUGMP, WHO GMP, ISO Certified, USFDA, Price, Cost, Manufacturer, Exporter, Supplier, India, China, MSDS
Queries
Easy ways to get the answers you need.
+91 79 65123395
+91 79 26463395
